3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Follicular
1
Dementia
1
Alzheimer Disease
1
Interventions
Rituximab
3
fludarabine phosphate
2
Etoposide
2
Cyclophosphamide
2
umbralisib
1
ublituximab
1
remdesivir
1
fludarabine
1
epratuzumab
1
aldesleukin
1
Whole-Body Irradiation
1
UE2343
1
Transplantation, Homologous
1
Transplantation, Autologous
1
Thiotepa
1
Therapeutics
1
Tacrolimus
1
Standard of Care
1
Sildenafil Citrate
1
Radiotherapy
1
Radioimmunodetection
1
Methotrexate
1
Melphalan
1
Hydrochlorothiazide
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Drug Therapy
1
Dosage Forms
1
Carmustine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Lymphoma, Follicular
×
UE2343
×
Clear all
NCT06125951
2026-04-23
XanaMIA
Actinogen Medical
Phase 2/3
Active not recruiting
247 enrolled